These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 1436703)

  • 1. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease.
    Pearson SJ; Reynolds GP
    Neurosci Lett; 1992 Sep; 144(1-2):199-201. PubMed ID: 1436703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is 3-hydroxykynurenine an endogenous neurotoxin in Huntington's disease?
    Guilarte TR; Eastman CL
    J Neurol Sci; 1993 Jun; 116(2):227-8. PubMed ID: 8336170
    [No Abstract]   [Full Text] [Related]  

  • 3. An investigation of the activities of 3-hydroxykynureninase and kynurenine aminotransferase in the brain in Huntington's disease.
    Pearson SJ; Meldrum A; Reynolds GP
    J Neural Transm Gen Sect; 1995; 102(1):67-73. PubMed ID: 8785025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?
    Guidetti P; Schwarcz R
    Adv Exp Med Biol; 2003; 527():137-45. PubMed ID: 15206726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model.
    Guidetti P; Reddy PH; Tagle DA; Schwarcz R
    Neurosci Lett; 2000 Apr; 283(3):233-5. PubMed ID: 10754231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased brain 3-hydroxykynurenine in Huntington's disease.
    Reynolds GP; Pearson SJ
    Lancet; 1989 Oct; 2(8669):979-80. PubMed ID: 2571888
    [No Abstract]   [Full Text] [Related]  

  • 7. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
    J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
    Tan L; Yu JT; Tan L
    J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia.
    Akbarian S; Smith MA; Jones EG
    Brain Res; 1995 Nov; 699(2):297-304. PubMed ID: 8616634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid.
    Beal MF; Matson WR; Swartz KJ; Gamache PH; Bird ED
    J Neurochem; 1990 Oct; 55(4):1327-39. PubMed ID: 2144582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tryptophan metabolites and brain disorders.
    Stone TW; Mackay GM; Forrest CM; Clark CJ; Darlington LG
    Clin Chem Lab Med; 2003 Jul; 41(7):852-9. PubMed ID: 12940508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical-clinical correlates in Huntington's disease--applications of brain banking techniques.
    Reynolds GP; Pearson SJ
    J Neural Transm Suppl; 1993; 39():207-14. PubMed ID: 8103075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tryptophan metabolism and oxidative stress in patients with Huntington's disease.
    Stoy N; Mackay GM; Forrest CM; Christofides J; Egerton M; Stone TW; Darlington LG
    J Neurochem; 2005 May; 93(3):611-23. PubMed ID: 15836620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex.
    Beal MF; Matson WR; Storey E; Milbury P; Ryan EA; Ogawa T; Bird ED
    J Neurol Sci; 1992 Mar; 108(1):80-7. PubMed ID: 1385624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's, and Parkinson's diseases.
    Metter EJ; Riege WH; Kameyama M; Kuhl DE; Phelps ME
    J Cereb Blood Flow Metab; 1984 Dec; 4(4):500-6. PubMed ID: 6238975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.
    Seeman P; Bzowej NH; Guan HC; Bergeron C; Reynolds GP; Bird ED; Riederer P; Jellinger K; Tourtellotte WW
    Neuropsychopharmacology; 1987 Dec; 1(1):5-15. PubMed ID: 2908095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered behavioral responses to gamma-aminobutyric acid pharmacological agents in a mouse model of Huntington's disease.
    Hsu YT; Chang YG; Chang CP; Siew JJ; Chen HM; Tsai CH; Chern Y
    Mov Disord; 2017 Nov; 32(11):1600-1609. PubMed ID: 28782830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct neuroinflammatory profile in post-mortem human Huntington's disease.
    Silvestroni A; Faull RL; Strand AD; Möller T
    Neuroreport; 2009 Aug; 20(12):1098-103. PubMed ID: 19590393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
    Heyes MP; Saito K; Crowley JS; Davis LE; Demitrack MA; Der M; Dilling LA; Elia J; Kruesi MJ; Lackner A
    Brain; 1992 Oct; 115 ( Pt 5)():1249-73. PubMed ID: 1422788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease.
    Bonda DJ; Mailankot M; Stone JG; Garrett MR; Staniszewska M; Castellani RJ; Siedlak SL; Zhu X; Lee HG; Perry G; Nagaraj RH; Smith MA
    Redox Rep; 2010; 15(4):161-8. PubMed ID: 20663292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.